Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Phase 2 Trial in Japan
jRCT2080223719Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, single-arm trial of avelumab in cancer, sponsored by Merck KGaA. Started Nov 2017; status: completed.
02
Drugs
avelumab
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223719.